LLY

Valuentum Stock Screeners

by

This article was sent to members via email December 29. That email can be accessed at the link that follows this article. By Brian Nelson, CFA Hi everyone, I wanted to provide an update with respect to Valuentum’s stock screeners. We believe our stock screeners are among the most robust when it comes to providing forward-looking data, or data that is important with respect to the investment decision-making process. We publish screens in each of the monthly newsletters, but we also provide a basic weekly screener for download on the left column of the website, “Download Weekly Stock Screener (xls) — login required.”   We also have other products. The more robust DataScreener, for example, is part of the quarterly Financial … Read more

Dividend Increases/Decreases for the Week Ending December 21

by

Below we provide a list of firms that raised their dividends during the week ending December 21. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week Abbot Laboratories (ABT): now $0.32 per share quarterly dividend, was $0.28. ABM Industries (ABM): now $0.18 per share quarterly dividend, was $0.175. Alamo (ALG): now $0.12 per share quarterly dividend, was $0.11. ALPS Alerian Energy Infrastructure ETF (ENFR): now $0.1863 per share quarterly dividend, was $0.17. ALPS Cohen & Steers Global Realty Majors ETF (GRI): now $0.4095 per share quarterly dividend, was $0.22. ALPS Equal Sector … Read more

Market Mayhem — Alerts for Members

by

During these extremely volatile times, it’s important to stay focused. On December 15, we informed all of our members to “Pay Attention.” Shortly thereafter, we notified members of the potential for a stock market technical breakdown. This morning, we offered a pre-market briefing about the importance of thinking about portfolio protection. For Best Ideas Newsletter and Dividend Growth Newsletter members: http://campaign.r20.constantcontact.com/render?preview=true&m=1110817109903&ca=e2406cd6-c113-4344-8731-493f33fc44a4&id=preview For High Yield Dividend Newsletter members: http://campaign.r20.constantcontact.com/render?preview=true&m=1110817109903&ca=b3ba530f-38b3-489a-ac96-2961dca89c6b&id=preview For Exclusive members: http://campaign.r20.constantcontact.com/render?preview=true&m=1110817109903&ca=ba6d90c0-4433-48b2-9b8a-aac4ddf9006e&id=preview We’re here for any questions. Please just let us know how we can help! Kind regards, Brian Nelson, CFA  brian@valuentum.com

Galapagos’ Filgotinib Scores Major Win for Gilead Sciences

by

Image source: Gilead second quarter earnings presentation Filgotinib posted stellar data in a recent phase 3 trial for the treatment of Rheumatoid Arthritis. In light of the data, we feel Galapagos and, by extension of their commercial partnership, Gilead Sciences possess a best in class molecule in immunology. By Alexander J. Poulos Key Takeaways Galapagos, which is ~15%-owned by Gilead Sciences, released stellar data of its lead compound Filgotinib.  Filgotinib again demonstrated a lack of clotting, which has torpedoed other competing promising molecules. In our opinion, Filgotinib is well on its way to a best in class profile which augurs well for Galapagos and its commercial partner Gilead Sciences. Though we continue to be cautious about any pharmaceutical/biotech idea, we … Read more

Stellar Keytruda Growth Powers Merck Higher

by

Shares of pharmaceutical giant Merck continue to accelerate thanks in large part to the growth of its key oncology asset Keytruda. Even though Merck is a well-established entity, future growth is highly correlated to the continued expansion of Keytruda as it continues to gain market share thanks in large part to superior clinical data and label expansion. By Alexander J. Poulos Key Takeaways Keytruda remains a star performer powering Merck’s quarterly performance. We remain big fans of Keytruda’s potential as the recent clinical data underscores the best in class potential of the molecule. The performance of Keytruda is critical for Merck as sales deceleration in former growth properties begin to weigh on overall sales of the company. Why are we … Read more

Eli Lilly Bursts Higher, Fair Value Estimate Under Review

by

We continue to be impressed with the recent developments at Eli Lilly as the company is poised to radically ramp sales growth potential in the event the commercialization of new products and its late-stage pipeline come to fruition. By Alexander J. Poulos Key Takeaways The share price of Eli Lilly has performed wonderfully of late as the company reported a beat-and-raise quarter thanks in large part to sales growth in newer products. Lilly scored a key patent win for its oncology mainstay Alimta, thus ensuring a steady revenue stream. With a patent win protecting Alimta, Lilly is in good shape to weather the revenue hit from a generic version of Cialis entering the market. We suspect Lilly will be able … Read more

Valuentum’s Weighted Average Cost of Capital (WACC) Distribution

by

The weighted average cost of capital is one of the most subjective measures in corporate finance, but it is also one of the most important ones. “The most important item over time in valuation is obviously interest rates…If interest rates are destined to be at low levels…It makes any stream of earnings from investments worth more money. The bogey is always what government bonds yield….Any investment is worth all the cash you’re going to get out between now and judgment day discounted back. The discounting back is affected by whether you choose interests rates like those of Japan or interest rates like those we had in 1982…When we had 15 percent short-term rates in 1982, it was silly to pay … Read more

AbbVie’s Outlook Remains Blurred

by

Image Source: Global Panorama We remain bearish on the outlook for AbbVie as we do not believe the clinical pipeline will be able to adequately offset the loss of revenue when key product Humira loses patent protection beginning in October as a biosimilar enters the European market. By Alexander J. Poulos Key Takeaways AbbVie remains over-reliant on sales of Humira to drive top-line sales–a major red flag as the worldwide patent protection is about to lapse. Humira will lose patent protection in Europe, and thus in our view, we think we are about to witness peak Humira sales in 2018. We feel investors are over-estimating the productivity of the clinical pipeline, and while there is always a chance AbbVie may … Read more

Eli Lilly Looks to Bolster Its Presence in Oncology

by

We are becoming increasingly impressed with Eli Lilly as the company boasts an enviable stable of new products that should power the company well into the next decade. Lilly is through the bulk of its patent trough, in our view, and its pipeline should set the company up for years of potentially uninterrupted revenue growth. Shares are not necessarily cheap, however. By Alexander J. Poulos Key Takeaways Lilly is aggressively building its oncology portfolio, and we think a new suite of recently-approved products should help power growth into the next decade. Lilly has opened the checkbook to acquire two additional novel compounds that underscore its desire to become a player in the oncology space. We view Lilly’s appetite for deal … Read more

Study: Valuentum’s Best Ideas Newsletter Portfolio

by

To read the study, please click on the image to download the pdf document (pdf).